Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease
Abstract Leucine-rich alpha-2 glycoprotein (LRG) may be a novel serum biomarker for patients with inflammatory bowel disease. The association of LRG with the endoscopic activity and predictability of mucosal healing (MH) was determined and compared with those of C-reactive protein (CRP) and fecal ma...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9402db5d6b1a4a128ee97bf9dc11e820 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9402db5d6b1a4a128ee97bf9dc11e820 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9402db5d6b1a4a128ee97bf9dc11e8202021-12-02T14:49:10ZLeucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease10.1038/s41598-021-90441-x2045-2322https://doaj.org/article/9402db5d6b1a4a128ee97bf9dc11e8202021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90441-xhttps://doaj.org/toc/2045-2322Abstract Leucine-rich alpha-2 glycoprotein (LRG) may be a novel serum biomarker for patients with inflammatory bowel disease. The association of LRG with the endoscopic activity and predictability of mucosal healing (MH) was determined and compared with those of C-reactive protein (CRP) and fecal markers (fecal immunochemical test [FIT] and fecal calprotectin [Fcal]) in 166 ulcerative colitis (UC) and 56 Crohn’s disease (CD) patients. In UC, LRG was correlated with the endoscopic activity and could predict MH, but the performance was not superior to that of fecal markers (areas under the curve [AUCs] for predicting MH: LRG: 0.61, CRP: 0.59, FIT: 0.75, and Fcal: 0.72). In CD, the performance of LRG was equivalent to that of CRP and Fcal (AUCs for predicting MH: LRG: 0.82, CRP: 0.82, FIT: 0.70, and Fcal: 0.88). LRG was able to discriminate patients with MH from those with endoscopic activity among UC and CD patients with normal CRP levels. LRG was associated with endoscopic activity and could predict MH in both UC and CD patients. It may be particularly useful in CD.Eriko YasutomiToshihiro InokuchiSakiko HiraokaKensuke TakeiShoko IgawaShumpei YamamotoMasayasu OhmoriShohei OkaYasushi YamasakiHideaki KinugasaMasahiro TakaharaKeita HaradaMasaki FurukawaKouichi ItoshimaKen OkadaFumio OtsukaTakehiro TanakaToshiharu MitsuhashiJun KatoHiroyuki OkadaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Eriko Yasutomi Toshihiro Inokuchi Sakiko Hiraoka Kensuke Takei Shoko Igawa Shumpei Yamamoto Masayasu Ohmori Shohei Oka Yasushi Yamasaki Hideaki Kinugasa Masahiro Takahara Keita Harada Masaki Furukawa Kouichi Itoshima Ken Okada Fumio Otsuka Takehiro Tanaka Toshiharu Mitsuhashi Jun Kato Hiroyuki Okada Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| description |
Abstract Leucine-rich alpha-2 glycoprotein (LRG) may be a novel serum biomarker for patients with inflammatory bowel disease. The association of LRG with the endoscopic activity and predictability of mucosal healing (MH) was determined and compared with those of C-reactive protein (CRP) and fecal markers (fecal immunochemical test [FIT] and fecal calprotectin [Fcal]) in 166 ulcerative colitis (UC) and 56 Crohn’s disease (CD) patients. In UC, LRG was correlated with the endoscopic activity and could predict MH, but the performance was not superior to that of fecal markers (areas under the curve [AUCs] for predicting MH: LRG: 0.61, CRP: 0.59, FIT: 0.75, and Fcal: 0.72). In CD, the performance of LRG was equivalent to that of CRP and Fcal (AUCs for predicting MH: LRG: 0.82, CRP: 0.82, FIT: 0.70, and Fcal: 0.88). LRG was able to discriminate patients with MH from those with endoscopic activity among UC and CD patients with normal CRP levels. LRG was associated with endoscopic activity and could predict MH in both UC and CD patients. It may be particularly useful in CD. |
| format |
article |
| author |
Eriko Yasutomi Toshihiro Inokuchi Sakiko Hiraoka Kensuke Takei Shoko Igawa Shumpei Yamamoto Masayasu Ohmori Shohei Oka Yasushi Yamasaki Hideaki Kinugasa Masahiro Takahara Keita Harada Masaki Furukawa Kouichi Itoshima Ken Okada Fumio Otsuka Takehiro Tanaka Toshiharu Mitsuhashi Jun Kato Hiroyuki Okada |
| author_facet |
Eriko Yasutomi Toshihiro Inokuchi Sakiko Hiraoka Kensuke Takei Shoko Igawa Shumpei Yamamoto Masayasu Ohmori Shohei Oka Yasushi Yamasaki Hideaki Kinugasa Masahiro Takahara Keita Harada Masaki Furukawa Kouichi Itoshima Ken Okada Fumio Otsuka Takehiro Tanaka Toshiharu Mitsuhashi Jun Kato Hiroyuki Okada |
| author_sort |
Eriko Yasutomi |
| title |
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| title_short |
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| title_full |
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| title_fullStr |
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| title_full_unstemmed |
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| title_sort |
leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/9402db5d6b1a4a128ee97bf9dc11e820 |
| work_keys_str_mv |
AT erikoyasutomi leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT toshihiroinokuchi leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT sakikohiraoka leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT kensuketakei leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT shokoigawa leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT shumpeiyamamoto leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT masayasuohmori leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT shoheioka leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT yasushiyamasaki leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT hideakikinugasa leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT masahirotakahara leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT keitaharada leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT masakifurukawa leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT kouichiitoshima leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT kenokada leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT fumiootsuka leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT takehirotanaka leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT toshiharumitsuhashi leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT junkato leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease AT hiroyukiokada leucinerichalpha2glycoproteinasamarkerofmucosalhealingininflammatoryboweldisease |
| _version_ |
1718389524100284416 |